<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04669535</url>
  </required_header>
  <id_info>
    <org_study_id>AXO-GM2-001</org_study_id>
    <nct_id>NCT04669535</nct_id>
  </id_info>
  <brief_title>A Dose-escalation and Safety &amp; Efficacy Study of AXO-AAV-GM2 in Tay-Sachs or Sandhoff Disease</brief_title>
  <official_title>A Two-Stage, Dose-Escalation and Safety &amp; Efficacy Study of Bilateral Intraparenchymal Thalamic and Intracisternal/Intrathecal Administration of AXO-AAV-GM2 in Tay-Sachs or Sandhoff Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sio Gene Therapies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sio Gene Therapies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The AXO-GM2-001 study is an open-label, two-stage clinical trial designed to evaluate safety&#xD;
      and dose-escalation (Stage 1) and safety and efficacy (Stage 2) of a bilateral thalamic and&#xD;
      intracisternal/intrathecal infusion of AXO-AAV-GM2 in pediatric participants with GM2&#xD;
      Gangliosidosis (also known as Tay-Sachs or Sandhoff Diseases), a set of rare and fatal&#xD;
      pediatric neurodegenerative genetic disorders caused by defects in the HEXA (leading to&#xD;
      Tay-Sachs disease) or HEXB (leading to Sandhoff disease) genes that encode the two subunits&#xD;
      of the β-hexosaminidase A (HexA) enzyme. AXO-AAV-GM2 is an investigational gene therapy that&#xD;
      aims to restore HexA function by introducing a functional copy of the HEXA and HEXB genes via&#xD;
      co-administration of two vectors utilizing the neurotropic adeno-associated virus recombinant&#xD;
      human 8 serotype (AAVrh.8) capsid carrying the human HEXA or HEXB cDNA.&#xD;
&#xD;
      The trial is expected to enroll pediatric participants with Tay-Sachs or Sandhoff Diseases,&#xD;
      where infantile-onset participants will range from 6 months to 20 months old, and&#xD;
      juvenile-onset participants will range from 2 years to 12 years old.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">June 2028</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, severity, seriousness and relatedness to treatment of treatment emergent adverse events</measure>
    <time_frame>48 weeks (infantile-onset participants) to 96 weeks (juvenile-onset participants)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal vital signs</measure>
    <time_frame>48 weeks (infantile-onset participants) to 96 weeks (juvenile-onset participants)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal physical exam per investigator assessment</measure>
    <time_frame>48 weeks (infantile-onset participants) to 96 weeks (juvenile-onset participants)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal clinical safety laboratory tests on blood/urine/CSF</measure>
    <time_frame>48 weeks (infantile-onset participants) to 96 weeks (juvenile-onset participants)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electroencephalograms alpha, beta, delta, and theta wave frequencies (Hz)</measure>
    <time_frame>48 weeks (infantile-onset participants) to 96 weeks (juvenile-onset participants)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cellular and antibody immune response to vector capsid/transgene</measure>
    <time_frame>48 weeks (infantile-onset participants) to 96 weeks (juvenile-onset participants)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Tay-Sachs Disease</condition>
  <condition>Sandhoff Disease</condition>
  <arm_group>
    <arm_group_label>AXO-AAV-GM2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AXO-AAV-GM2 infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AXO-AAV-GM2 Starting Dose</intervention_name>
    <description>1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).</description>
    <arm_group_label>AXO-AAV-GM2</arm_group_label>
    <other_name>AAVrh8-HEXA and AAVrh8-HEXB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AXO-AAV-GM2 Low Dose</intervention_name>
    <description>1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).</description>
    <arm_group_label>AXO-AAV-GM2</arm_group_label>
    <other_name>AAVrh8-HEXA and AAVrh8-HEXB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AXO-AAV-GM2 Middle Dose</intervention_name>
    <description>1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).</description>
    <arm_group_label>AXO-AAV-GM2</arm_group_label>
    <other_name>AAVrh8-HEXA and AAVrh8-HEXB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AXO-AAV-GM2 High Dose</intervention_name>
    <description>1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).</description>
    <arm_group_label>AXO-AAV-GM2</arm_group_label>
    <other_name>AAVrh8-HEXA and AAVrh8-HEXB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects born between 37 - 42 weeks gestation with genetically&#xD;
             diagnosed TSD or SD mutations of either HEXA gene or HEXB gene&#xD;
&#xD;
             a. Juvenile-onset subjects must be ≥ 2 years old and ≤ 12 years old at time of gene&#xD;
             transfer&#xD;
&#xD;
             i. Diagnosis consistent with juvenile-onset TSD or SD&#xD;
&#xD;
             b. Infantile-onset subjects must be between 6-20 months of age at the time of gene&#xD;
             transfer&#xD;
&#xD;
             i. Diagnosis consistent with infantile-onset TSD or SD&#xD;
&#xD;
             ii. Current or historical ability to sit without support for at least 5 seconds&#xD;
&#xD;
          2. Surgical readiness for gene transfer by the routes of administration confirmed by the&#xD;
             study neurosurgeon, based on examination and magnetic resonance imaging (MRI) findings&#xD;
&#xD;
          3. Subjects receiving off-label Zavesca® (miglustat) and/or Tanganil® (acetyl-leucine)&#xD;
             must be willing to discontinue these therapies 30 days prior to the start of screening&#xD;
&#xD;
          4. Ability to reliably travel to the study sites for study visits according to the&#xD;
             Schedule of Assessments&#xD;
&#xD;
          5. Subjects must have a swallowing evaluation test performed (within 6 months) prior to&#xD;
             administration of gene replacement therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of G269S or W574C mutation&#xD;
&#xD;
          2. History of drug-resistant seizures or status epilepticus&#xD;
&#xD;
          3. History and/or findings of spinal cord disease that would preclude the lumbar puncture&#xD;
             and ICM/IT infusion procedures&#xD;
&#xD;
          4. The subject's parent(s) or legal guardian(s) is unable to understand the nature,&#xD;
             scope, and possible consequences of the study, or does not agree to comply with the&#xD;
             protocol defined schedule of assessments&#xD;
&#xD;
          5. Any prior participation in a study in which a gene therapy vector or stem cell&#xD;
             transplantation was administered&#xD;
&#xD;
          6. Immunizations of any kind in the month prior to screening&#xD;
&#xD;
          7. Cardiomyopathy or other cardiac disease based on echocardiogram and/or&#xD;
             electrocardiogram, (ECG) that in the opinion of the Investigator would deem the&#xD;
             subject unsafe to undergo surgical gene transfer&#xD;
&#xD;
          8. Indwelling ferromagnetic devices that would preclude MRI//MRS/DTI imaging&#xD;
&#xD;
          9. Ongoing medical condition that is deemed by the Investigator to interfere with the&#xD;
             conduct or assessments of the study&#xD;
&#xD;
         10. Current clinically significant infections including any requiring systemic treatment&#xD;
             including but not limited to human immunodeficiency virus (HIV), Hepatitis A, B, or C&#xD;
&#xD;
         11. History of or current chemotherapy, radiotherapy or other immunosuppressive therapy&#xD;
             within the past 30 days. Corticosteroid treatment may be permitted at the discretion&#xD;
             of the PI&#xD;
&#xD;
         12. Clinically significant laboratory abnormalities in liver functional tests, hematology,&#xD;
             and blood chemistry parameters&#xD;
&#xD;
         13. Subjects for whom any of the proposed study procedures or medications would be&#xD;
             contraindicated&#xD;
&#xD;
         14. Failure to thrive, defined as falling 20 percentiles (20/100) in body weight in the 3&#xD;
             months preceding Screening/Baseline&#xD;
&#xD;
         15. Subject is not suitable for participation in the study in the opinion of the Principal&#xD;
             Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erika De Boever, DDS, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sio Gene Therapies</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials</last_name>
    <phone>646-887-2651</phone>
    <email>patients@siogtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital, Center for Rare Neurological Diseases</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Eichler, MD</last_name>
      <phone>617-724-6510</phone>
      <email>feichler@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Haley Andonian</last_name>
      <phone>617-724-1379</phone>
      <email>handonian@partners.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical Health Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terence Flotte, MD</last_name>
      <phone>508-856-2107</phone>
      <email>Terry.flotte@umassmed.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karen Longtine, RN</last_name>
      <phone>508-856-6970</phone>
      <email>Karen.Longtine@umassmed.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GM2 Gangliosidosis</keyword>
  <keyword>Hexosaminidase A Deficiency</keyword>
  <keyword>HexA Deficiency</keyword>
  <keyword>TSD</keyword>
  <keyword>SD</keyword>
  <keyword>Lysosomal Storage Disorders</keyword>
  <keyword>Tay-Sachs Disease</keyword>
  <keyword>Sandhoff Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tay-Sachs Disease</mesh_term>
    <mesh_term>Sandhoff Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

